Industry ExaminerMar 26

Merck’s $6.7B Terns buy is less about leukemia than life after Keytruda.

When one drug drives nearly half of revenue, M&A becomes a way to buy time before the patent cliff.

Read:
https://biotech.industryexaminer.com/merck-terns-deal-keytruda-patent-cliff-biotech-m-and-a/

#Biotech #Pharma #Merck #Oncology #PatentCliff #BiotechM&A #TechNews #BioTechne

Merck’s $6.7 billion Terns deal is really a bet on life after Keytruda - Biotech Industry Examiner

The target is a leukemia drug developer. The real objective is something larger: time, diversification, and a more believable post-Keytruda growth story.

Biotech Industry Examiner
ExTraders GlobalOct 30, 2024

Dayforce ($DAY) reported EPS of $0.47, exceeding the forecast of $0.4294. Revenue was $440M, surpassing the expected $428.34M.

Bio-Techne ($TECH) achieved EPS of $0.42, beating the forecast of $0.38. Revenue reached $289.5M, exceeding the anticipated $280.22M.

Bunge ($BG) posted EPS of $2.29, higher than the forecast of $2.14. However, revenue was $12.91B, falling short of the expected $13.34B.

#Earnings #Q3 #Dayforce #BioTechne #Bunge #Investing #Finance #Stocks #MarketNews